Akero Therapeutics Stock Doubles on Liver Disease Drug Trial Results | Global News Avenue

Akero therapeutics’s shares (Acro) On Monday, a pharmaceutical company focusing on metabolic diseases reported the positive research on the research on the treatment of liver disease.

The company said 96 weeks 2B stage research In patients with cirrhosis caused by metabolic dysfunction -related fatty hepatitis (MASH), EFRUXIFERMIN (EFX) of 50 mg doses of drugs show that 39 % of people have experienced the reversal of Cirrhosis without causing MASH reversal Essence In contrast, only 15 % of placebo.

Akero pointed out that the sub-group of patients who do not use GLP-1 weight loss pills, such as Novo Nordisk (Novo Nordisk’s) (Non -governmental organization) Wegovy and Eli Lilly (Liberal) The results of Zepbound are even better, indicating that these drugs are not the source of improvement.

The main researcher of this study Dr. Mozu Nuredin said until now: “We have not effectively treated compensated liver hardening caused by potato puree.” Dr. Nourredin added: “Now, we have reasons for EFX as an urgent need of liver that urgently needed liver. The future potential of hardening is optimistic. ”

Dr. Andrew Cheng, the CEO, explained that EFX has “the potential of change”, and the company continues to evaluate the treatment in the 3 -stage test of the company.

Akero therapeutics stocks traded at the highest level of history more than two years ago.